ACS Chemical Biology
Page 8 of 9
1
2
3
References
4
5
6
7
8
9
1. Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T.,
Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., Sozen, M. M., Baimukanova, G., Roy,
R., Heguy, A., Dolgalev, I., Khanin, R., Busam, K., Speicher, M. R., O'Brien, J., and Bastian, B. C.
(2010) Mutations in GNA11 in uveal melanoma, N Engl J Med 363, 2191-2199.
2. Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J. M., Simpson, E.
M., Barsh, G. S., and Bastian, B. C. (2009) Frequent somatic mutations of GNAQ in uveal
melanoma and blue naevi, Nature 457, 599-602.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3. Chen, X., Wu, Q., Depeille, P., Chen, P., Thornton, S., Kalirai, H., Coupland, S. E., Roose, J. P., and
Bastian, B. C. (2017) RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal
Melanoma, Cancer Cell 31, 685-696 e686.
4. Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M.
R., Ksander, B. R., Merlino, G., Sodhi, A., Chen, Q., and Gutkind, J. S. (2014) Hippo-independent
activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase
signaling circuitry, Cancer Cell 25, 831-845.
5. Yu, F. X., Luo, J., Mo, J. S., Liu, G., Kim, Y. C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W.,
Zhao, J., Chen, X., Zhang, L., Wang, C. Y., Bastian, B. C., Zhang, K., and Guan, K. L. (2014) Mutant
Gq/11 promote uveal melanoma tumorigenesis by activating YAP, Cancer Cell 25, 822-830.
6. Amirouchene-Angelozzi, N., Nemati, F., Gentien, D., Nicolas, A., Dumont, A., Carita, G., Camonis, J.,
Desjardins, L., Cassoux, N., Piperno-Neumann, S., Mariani, P., Sastre, X., Decaudin, D., and
Roman-Roman, S. (2014) Establishment of novel cell lines recapitulating the genetic landscape
of uveal melanoma and preclinical validation of mTOR as a therapeutic target, Mol Oncol 8,
1508-1520.
7. Wu, X., Li, J., Zhu, M., Fletcher, J. A., and Hodi, F. S. (2012) Protein kinase C inhibitor AEB071
targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and
PKC/NF-kappaB pathways, Mol Cancer Ther 11, 1905-1914.
8. Wu, X., Zhu, M., Fletcher, J. A., Giobbie-Hurder, A., and Hodi, F. S. (2012) The protein kinase C
inhibitor enzastaurin exhibits antitumor activity against uveal melanoma, PLoS One 7, e29622.
9. Piperno-Neumann, S., Kapiteijn, E., Larkin, J., Carvajal, R. D., Luke, J. J., Seifert, H., Roozen, I.,
Zoubir, M., Yang, L., Choudhury, S., Yerramilli-Rao, P., Hodi, F. S., and Schwartz, G. K. (2014)
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with
metastatic uveal melanoma, In ASCO annual meeting 2014, J. Clin. Oncol (abstr 9030).
10. Heijkants, R. C., Nieveen, M., Hart, K. C., Teunisse, A., and Jochemsen, A. G. (2018) Targeting
MDMX and PKCdelta to improve current uveal melanoma therapeutic strategies, Oncogenesis
7, 33.
11. Takashima, A., English, B., Chen, Z., Cao, J., Cui, R., Williams, R. M., and Faller, D. V. (2014) Protein
kinase Cdelta is a therapeutic target in malignant melanoma with NRAS mutation, ACS Chem
Biol 9, 1003-1014.
12. Jager, M. J., Magner, J. A., Ksander, B. R., and Dubovy, S. R. (2016) Uveal Melanoma Cell Lines:
Where do they come from? (An American Ophthalmological Society Thesis), Trans Am
Ophthalmol Soc 114, T5.
13. Chen, X., Wu, Q., Tan, L., Porter, D., Jager, M. J., Emery, C., and Bastian, B. C. (2014) Combined
PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations, Oncogene 33,
4724-4734.
14. Evenou, J. P., Wagner, J., Zenke, G., Brinkmann, V., Wagner, K., Kovarik, J., Welzenbach, K. A.,
Weitz-Schmidt, G., Guntermann, C., Towbin, H., Cottens, S., Kaminski, S., Letschka, T., Lutz-
Nicoladoni, C., Gruber, T., Hermann-Kleiter, N., Thuille, N., and Baier, G. (2009) The Potent
Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of
Immunosuppressive Agents Affecting Early T-Cell Activation, Journal of Pharmacology and
Experimental Therapeutics 330, 792-801.
15. Soltoff, S. P. (2007) Rottlerin: an inappropriate and ineffective inhibitor of PKC delta, Trends
Pharmacol Sci 28, 453-458.
ACS Paragon Plus Environment